Groups Call On CMS To Maintain Floor Hemoglobin Target For ESRD Payment
Executive Summary
CMS’ proposal to retire the floor hemoglobin level of 10 g/dL as part of the quality incentive program for the end stage renal disease prospective payment system is being challenged with the argument that it could lead to under treatment of anemia and an increase in blood transfusions.
You may also be interested in...
Medicare Proposes Changes To Target Hemoglobin Levels In ESRD Treatment
CMS aims at “retiring” the floor hemoglobin level of 10 g/dL and lowering the target upper level to 11 g/dL in its proposed rule for the Medicare Part B prospective payment system for treatment of end-stage renal disease, a move that could apply more pressure to Amgen’s erythropoiesis-stimulating agents franchise.
Epogen Facing Sales Hit With Reduced Dosing Instructions In ESA Labeling For Renal Disease
Amgen agrees to studies to find what FDA calls "better, safer dose regimen strategies" as ESA labeling revisions create more conservative dosing guidelines for the products.
FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees
Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.